Stocks
GlaxoSmithKline (GSK) EBITDA margin US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 25.8% | 30.0% | 30.0% | 31.0% | 30.6% | 30.2% | ||
| Changes by years, y/y, % | 0pp | +4pp | 0pp | +1pp | 0pp | +5.1% | |||
GlaxoSmithKline. EBITDA margin, %
GlaxoSmithKline. EBITDA margin, changes, pp
GlaxoSmithKline (GSK) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | 36.6% | 31.3% | 27.7% | 27.7% | 34.4% | 30.2% | |
| Changes by years, y/y, % | +12pp | +4pp | +2pp | +2pp | -5pp | |||
| Changes by quarters, q/q, % | 0pp | -5pp | -4pp | 0pp | +7pp | |||
